TIM ‐4 increases the proportion of CD4 + CD25 + FOXP3 + regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL ‐6 secretion
Cancer Medicine · 2024
DOI: 10.1002/cam4.70110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Ziyao Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Tumor Microenvironment, Interleukin-6, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: West China Hospital Clinical Research Incubation Project, the 1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project of West China Hospital: ZYJC21037.
Abstract (Originalsprache)
Background
Currently, creating more effector T cells and augmenting their functions is a focal point in pancreatic ductal adenocarcinoma (PDAC) treatment research. T cell immunoglobulin domain and mucin domain molecule 4 (TIM‐4), known for promoting cancer progression in various malignancies, is implicated in the suppressive immune microenvironment of tumors. Analyzing of the role of TIM‐4 in the immune regulation of PDAC can offer novel insights for immune therapy.
Methods
We analyzed the TIM‐4 expression in tumor specimens from PDAC patients. Meanwhile, multiple fluorescent immunohistochemical staining was used to study the distribution characteristics of TIM‐4, and through tissue microarrays, we explored its correlation with patient prognosis. The influence of TIM‐4 overexpression on cell function was analyzed using RNA‐seq. Flow cytometry and ELISA were used for verification. Finally, the relationship between TIM‐4 and T lymphocytes was analyzed by tissue microarray, and the impacts of TIM‐4 on T cell subsets were observed by cell coculture technology and a mouse pancreatic cancer in situ model.
Results
In PDAC, TIM‐4 is mainly expressed in tumor cells and negatively correlated with patient prognosis. TIM‐4 influences the differentiation of Treg by inhibiting IL‐6 secretion in pancreatic cancer cells and facilitates the proliferation of pancreatic cancer in mice. Additionally, the mechanism may be through the CD8 + effector T cells (CD8 + Tc).
Conclusion
TIM‐4 has the potential to be an immunotherapeutic target or to improve the efficacy of chemotherapy for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
- Department of General Surgery, West China Tianfu Hospital, Sichuan University, Chengdu, China.
- Department of Biochemistry and Molecular Biology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, China.
- Department of Radiology, The First People's Hospital of Chengdu, Chengdu, China.
ORCID-Profile: Nengwen Ke
Förderung
- West China Hospital Clinical Research Incubation Project
- the 1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project of West China Hospital: ZYJC21037
Zitieren
APA
Wang, Z., Xie, Z., Mou, Y., Geng, R., Chen, C., & Ke, N. (2024). TIM ‐4 increases the proportion of CD4 + CD25 + FOXP3 + regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL ‐6 secretion. Cancer Medicine. https://doi.org/10.1002/cam4.70110
Vancouver
Wang Z, Xie Z, Mou Y, Geng R, Chen C, Ke N. TIM ‐4 increases the proportion of CD4 + CD25 + FOXP3 + regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL ‐6 secretion. Cancer Medicine. 2024. doi:10.1002/cam4.70110
BibTeX
@article{Wang2024,
author = {Wang, Ziyao and Xie, Zerong and Mou, Yu and Geng, Ruiman and Chen, Chen and Ke, Nengwen},
title = {TIM ‐4 increases the proportion of CD4 + CD25 + FOXP3 + regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL ‐6 secretion},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70110}
}
EUVIMED